Astera Labs, Inc.
257.16USD
-0.6600 (-0.26%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ALAB.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 79.9M | 115.8M | 396.3M | 852.5M | 1.9B | 3.0B |
| Q1 | — | 17.7M | 65.3M | 159.4M | 308.4M | — |
| Q2 | — | 10.7M | 76.9M | 191.9M | 392.4M | — |
| Q3 | — | 36.9M | 113.1M | 230.6M | 550.8M | — |
| Q4 | — | 50.5M* | 141.1M* | 270.6M* | 655.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.484 | -.201 | -.640 | 1.22 | 4.03 | 6.40 |
| Q1 | — | -.139 | -.708 | .180 | .440 | — |
| Q2 | — | -.156 | -.050 | .290 | .830 | — |
| Q3 | — | -.023 | -.050 | .500 | 1.19 | — |
| Q4 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .109* |
| .188* |
| .251* |
| 1.42 |
| — |
Debt level and coverage